#CheckYourMedsDay #MedicationSafety #PatientEducation #PatientEngagement #HealthcareInnovation #MedicalEducation #HealthEquity #PharmaStrategy #MarketAccess To view or add a comment, sign in FDA Alert: Nitrosamines in Infusion Bags On Aug 18, 2025, the FDA flagged N-nitrosodibutylamine (NDBA) and other small-molecule nitrosamines in some drug products packaged in infusion bags

Water, Ammonium Lauryl Sulfate, Glycerin, 1.2-Hexanediol, Lauryl Glucoside, Cocamidopropyl Betaine, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Hydrolyzed Sodium Hyaluronate (9,740 ppm), Tromethamine, Sodium Chloride, Citric Acid, Sodium Benzoate, Glutathione, Disodium EDTA, Hydrogenated Lecithin, Maltodextr Polyglyceryl-10 Stearate, Polyglyceryl-4 Caprate, Hydrolyzed Gardenia Florida Extract, Butylene Glycol, Niacinamide, Glyceryl Glucoside, Silybum Marianum Extract Dimethylsilanol Hyaluronate (300 ppb), Sodium Hyaluronate (200 ppb), Polyglyceryl-10 Laurate, Hyaluronic Acid (50 ppb), Hydrolyzed Hyaluronic Acid (50 ppb), Hydroxypropyltrimonium Hyaluronate (50 ppb), Potassium Hyaluronate (35 ppb), Copper Tripeptide-1, Sodium Acetylated Hyaluronate (15 ppb), Acetyl Hexapeptide-Cyanocobalamin, Pyridoxine HCI, Palmitoyl Pentapeptide-4, Palmitoyl Tetrapeptide-7, Palmitoyl Tripeptide-1, Riboflavin, Fragrance, Hexyl Cinnamal

IBD and Colitis Evidence Multiple mouse models of colitis support KPV's gut-specific efficacy
Humans are available through the patient portal, but expect about a day for follow-up, though the customer service is where Fridays really shines for proactive communication